About this trial

This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease. Hyperspectral imaging captures retinal data across multiple wavelengths to generate detailed spectral information that may reveal features not visible with conventional retinal photography.

Approximately 1000 participants will undergo multi-modal ophthalmic imaging in Melbourne, Australia, including hyperspectral imaging, OCT, fundus photography, and related tests. The study aims to compare hyperspectral imaging with standard imaging methods and assess its ability to identify retinal biomarkers associated with diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration.

Eligibility criteria

Qualifiers

Adults aged 18 years and older

Able to provide informed consent

Willing and able to attend a study visit at the Centre for Eye Research Australia

Participants with diagnosed retinal or optic nerve disease (e.g., diabetic retinopathy, glaucoma, age-related macular degeneration)

Disqualifiers

Inability to provide informed consent

Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage)

Known contraindication to pharmacological pupil dilation

History of narrow anterior chamber angle or risk of angle closure glaucoma where dilation is considered unsafe

Trial design

Treatments tested in this trial

  • Hyperspectral camera

Treatment groups

1,000 Participants
are divided into 1 treatment group

Locations

1
The Centre for Eye Research Australia3002, MelbourneVictoria, Australia

Sponsors and collaborators

Center for Eye Research Australia

Lead sponsor